Aurora A: target invalidated?
Aurora kinases are important mitotic regulators, and Aurora kinase inhibitors are under investigation as treatments for cancer. An ongoing debate in the field is which Aurora kinase is the better drug target. A new study (Girdler et al., 2008, in this issue of Chemistry & Biology) pushes the case forward for Aurora B.
Cochran
Andrea G
AG
Department of Protein Engineering, Genentech Inc, South San Francisco, CA 94080, USA. andrea@gene.com
D000970:Antineoplastic Agents / Q000494:pharmacology*; D064107:Aurora Kinase B; D064127:Aurora Kinases; D006801:Humans; D008938:Mitosis / Q000187:drug effects / Q000502:physiology; D009369:Neoplasms / Q000201:enzymology* / Q000473:pathology; D047428:Protein Kinase Inhibitors / Q000494:pharmacology*; D017346:Protein Serine-Threonine Kinases / Q000037:antagonists & inhibitors* / Q000378:metabolism
D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; C576921:AURKB protein, human; D064107:Aurora Kinase B; D064127:Aurora Kinases; D017346:Protein Serine-Threonine Kinases